Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Recent News

  • Oct 13, 2017

    GAITHERSBURG, Md. , Oct. 13, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) announced today that Barclay A. “Buck” Phillips has submitted his resignation as Senior Vice President, Chief Financial Officer (CFO) and Treasurer, to pursue an expanded opportunity in the industry. Mr....More>>

  • Sep 19, 2017

    GAITHERSBURG, Md. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced the Company will present at the Ladenburg Thalmann 2017 Healthcare Conference. Presentation details are as follows: Date: Tuesday, September 26, 2017 Time: 11:00 – 11:25 am ET Location: Track 5,...More>>

  • Sep 19, 2017

    Recently published NanoFlu™ preclinical data provide strong rationale for Phase 1/2 clinical trial based on robust antibody titers and improved protective responses against both current and drifted strains Data from trial expected by the end of 2017 GAITHERSBURG, Md. , Sept....More>>

Stock Quote